An issue that should be considered is the potential toxicity of ICIs to the cardiovascular system
DOI:
https://doi.org/10.54097/yg1cqc27Keywords:
Immune checkpoint inhibitors; cardiovascular toxicity; Immune-related adverse events.Abstract
An important consideration is the potential cardiovascular toxicity of immune checkpoint inhibitors (ICIs) in cancer therapy, given their increasing popularity and revolutionizing effects on certain treatment regimens. However, ICIs also exhibit unavoidable side effects such as immune-related adverse events (irAEs), which are particularly significant due to their interaction with underlying diseases. This review aims to explore the reported cardiovascular toxicity in patients treated with ICIs, providing insights into potential mechanisms, monitoring methods, and management strategies for the rational use of these drugs. The awareness of ICIs' use is crucial for clinicians as these adverse immune events can interact with the patient's underlying disease. This review focuses on cardiovascular toxicity reported in patients after ICI usage, aiming to elaborate potential mechanisms, monitoring methods, and management strategies that may inspire rational clinical use of ICIs.
Downloads
References
Meilhac A, Cautela J, Thuny F. Cancer Therapies and Vascular Toxicities. Curr Treat Options Oncol, 2022, 23(3): 333-47.
Wang J, Liu F, Li J, et al. Fruit and vegetable consumption, cardiovascular disease, and all-cause mortality in China. Sci China Life Sci, 2022, 65(1): 119-28.
Kottschade L A. Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors. Curr Oncol Rep, 2018, 20(3): 24.
Heinzerling L, Ascierto P A, Dummer R, et al. Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology. Eur J Cancer, 2019, 112: 29-31.
Coustal C, Vanoverschelde J, Quantin X, et al. Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series. J Immunother Cancer, 2023, 11(5).
Tan S, Day D, Nicholls S J, et al. Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol, 2022, 4(5): 579-97.
Nave O, Elbaz M, Bunimovich-Mendrazitsky S. Analysis of a breast cancer mathematical model by a new method to find an optimal protocol for HER2-positive cancer. Biosystems, 2020, 197: 104191.
Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol, 2020, 17(8): 807-21.
Hu J R, Florido R, Lipson E J, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res, 2019, 115(5): 854-68.
Wu Mengchao, Wu Zaid, Wu Zhaohan; edited by Chen Xiaoping, Wang Jianping, Zhao Jizong; associate edited by Qin Xinyu, Liu Yucun, Zhang Yingze, Sun Yinghao, Li Zongfang. Surgery 9th edition. Beijing: People's Health Publishing House, 2018.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
